#USA #San Francisco #securities lawsuit #FDA Regulations #Capricor Therapeutics

Capricor Therapeutics Faces Significant Uncertainty Post Q2 Earnings

Capricor Therapeutics, Inc. (NASDAQ: CAPR) recently released its Q2 2026 earnings report, which has drawn significant attention due to its concurrent ongoing legal issues, particularly a securities class action lawsuit. The law firm Hagens Berman, known for advocating on behalf of investors, has highlighted these troublesome developments surrounding the company as they navigate these turbulent waters.

Earnings Report Overview

In the earnings report, Capricor announced a staggering net loss of $40.7 million while holding approximately $237.9 million in cash and marketable securities. This loss raised eyebrows, especially in light of the company's omission of a question-and-answer session typically held after such reports. When questioned about this omission, management stated it was due to the sensitive nature of discussions with the FDA regarding their regulatory pathway. However, this decision has left many investors feeling uneasy about the integrity of the trial data and the potential ramifications of the ongoing legal issues.

Ongoing Legal Challenges

The securities class action lawsuit pertains to allegations that Capricor and certain executives misled investors about the integrity of clinical trial data for their lead product candidate, Deramiocel, designed for treating Duchenne muscular dystrophy (DMD). The lawsuit alleges that critical changes to the Statistical Analysis Plan (SAP) were made without proper disclosure or agreement from the FDA, thus compromising the trial’s validity. This situation became particularly alarming following a pivotal announcement made on December 3, 2025, where Capricor reported positive results from the Phase 3 HOPE-3 Trial.

These results initially prompted a significant surge in Capricor's stock price, jumping 370% to $23.60 per share. However, following the subsequent FDA briefing that revealed unapproved changes to the SAP, the company faced a catastrophic decline, with shares plummeting 64% to close at $7.00. The FDA’s results indicated that the HOPE-3 study failed to meet critical efficacy endpoints, which exacerbated the negative sentiment among investors, further deepening Capricor's financial woes.

What This Means for Investors

For investors affected, the lead plaintiff deadline in the class action suit is set for September 28, 2026. Hagens Berman invites investors who purchased securities from December 17, 2025, to July 26, 2026, and have incurred significant losses, to come forward and seek guidance. Legal action may provide a pathway for recovery, especially as the firm investigates how management handled disclosures regarding trial endpoints and unreported plan modifications.

Next Steps

Investors are urged to assess their position regarding Capricor's recent performance and consider their rights under the law. Moreover, those with non-public information about the company should contemplate cooperating with the investigation, especially as whistleblowers could potentially qualify for rewards up to 30% of recovered amounts by the SEC.

Hagens Berman's Commitment

Hagens Berman is dedicated to standing up for investors and holding corporations accountable for their actions. With a proven track record, the firm has secured more than $2.9 billion for clients harmed by corporate negligence. For further details, investors can reach out via their website or directly contact Reed Kathrein, who is leading the investigation on these pressing matters.

In conclusion, as Capricor Therapeutics navigates these turbulent times post-Q2 earnings, both the legal stakes and investor concerns become intertwined, highlighting the importance of transparency in corporate governance and communication.